Results for
"[search-keyword]"
Sponsor content
176 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 16.67 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 12.5 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EBGLYSS lebrikizumab 250 mg/2 mL solution for injection autoinjector (pre-filled pen).
-
Aug-2024Prescription medicine evaluationActive ingredient: mirikizumab.
-
-
Prescription medicine decision summaryEbglyss (lebrikizumab) is for the treatment of moderate to severe atopic dermatitis (atopic eczema) in patients older than the age of twelve.
-
Prescription medicine registrationActive ingredients: lebrikizumab.
-
Australian Public Assessment Report (AusPAR)Omvoh (mirikizumab) has been approved for the treatment of moderately to severely active ulcerative colitis in adult patients
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd